Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Fluent, Inc. Director's Dealing 2025

Aug 21, 2025

34456_dirs_2025-08-21_4fb4cd29-cead-4f4c-aa94-e32fd7d752a1.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Fluent, Inc. (FLNT)
CIK: 0001460329
Period of Report: 2025-08-19

Reporting Person: FROST PHILLIP MD ET AL (10% Owner)
Reporting Person: Frost Gamma Investments Trust (10% Owner)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-08-19 Pre-Funded Warrants $0.0005 A 571429 Acquired Common Stock (571429) Indirect
2025-08-19 Warrants $2.21 A 571429 Acquired Common Stock (571429) Indirect

Footnotes

F1: These securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole stockholder of Frost-Nevada Corporation. The reporting persons disclaim beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that any reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F2: Each Pre-Funded Warrant is immediately exercisable for one share of the issuer's common stock, $0.0005 par value per share (the "Common Stock"), and will expire when exercised in full.

F3: Each Warrant will be exercisable for one share of Common Stock at any time on or after the date that is six months and one day following the date of issuance for a period of five and one-half years from the date of issuance. Notwithstanding the foregoing, the Warrants shall be exercisable at any time on or after the date that applicable stockholder approval is obtained and deemed effective and such Warrants shall be exercisable until the expiration date.